⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709020 | 0.85 | — | — | |
| SCHEMBL15942705 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL29951194 | 0.64 | BLM (0.50) | — | |
| SCHEMBL28475397 | 0.59 | — | — | |
| SCHEMBL8207232 | 0.58 | — | — | |
| SCHEMBL14207032 | 0.58 | — | — | |
| SCHEMBL30037332 | 0.57 | — | — | |
| SCHEMBL28469386 | 0.57 | — | — | |
| SCHEMBL6053024 | 0.56 | — | — | |
| Piperazine SCHEMBL27934041 | 0.43 | HIF1A (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802119-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8541581-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541581-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS ,INC (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088738-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS ,INC (US) | 2012-04-12 | — | — | US | disclosed |
| WO-2010118159-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |